Developer docs
API playgroundTry for free, no card

Search company profiles

Achieve TMS

Full company profile

uuid002dr5d

Namestring
Achieve TMS
Legal namestring
Greenbrook TMS NeuroHealth Centers
Websiteurl
achievetms.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Achieve TMS is a private healthcare services provider founded in 2016 and headquartered in San Diego that delivers FDA-cleared and FDA-approved depression treatments to adults suffering from major depressive disorder, including treatment-resistant depression. The company operates physical clinic locations where patients receive in-person treatment, and its core offerings are NeuroStar TMS Therapy (transcranial magnetic stimulation, FDA-cleared) and SPRAVATO (esketamine nasal spray, FDA-approved), both supplied through technology and licensing partnerships with Neuronetics and Janssen Pharmaceuticals respectively. The treatments target adults with depression, particularly those who have not achieved relief through traditional antidepressant medications or talk therapy, and patients with MDD accompanied by suicidal ideation.

The company generates revenue by delivering recurring treatment services at clinic locations, with most major insurance plans, Medicare, and Medicaid providing coverage at various sites. Pricing is not publicly disclosed; instead, the company manages the entire insurance workflow on behalf of patients — including coverage verification, claims filing, and appeals — which serves as a patient-friction-reduction mechanism and a core part of the value proposition. Patient acquisition runs through direct-to-consumer channels including a toll-free consultation line, online PHQ-9/PHQ-10 self-assessment quizzes, website content, and patient testimonial stories, with a separate provider-referral pathway for clinicians.

The business model is that of a clinic operator rather than a product manufacturer: Achieve TMS delivers externally-developed FDA-regulated treatments through its own physical footprint and operational infrastructure. Strategic relationships with the technology licensors (Neuronetics, Janssen), insurance carriers, and LegitScript (for healthcare merchant verification) form the operational backbone, and HIPAA compliance is maintained for patient data handling. No funding rounds, M&A activity, leadership details, or headcount data are disclosed in the source material, limiting visibility into the company's scale and capital structure.

Short descriptiontext

Achieve TMS is a private healthcare provider founded in 2016 in San Diego that operates clinics delivering FDA-cleared NeuroStar TMS therapy and FDA-approved SPRAVATO esketamine treatments to adults with depression, particularly treatment-resistant depression.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
TMS therapy services, depression treatment, esketamine treatment, transcranial magnetic stimulation, mental health clinics
NAICS code2 codes
  • Outpatient Mental Health and Substance Abuse Centers621420
  • Offices of Physicians, Mental Health Specialists621112
SIC code2 codes
  • Services-Specialty Outpatient Facilities, Nec8093
  • Services-Offices & Clinics Of Doctors Of Medicine8011
Product category
Mental Health Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Patient Treatment Services
TypeSubscription Recurring
Description

Revenue generated from providing TMS therapy and esketamine treatment services to patients at clinic locations. Treatments are typically covered by insurance including Medicare and Medicaid.

greenbrooktms.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2C
B2C
Offering typeServices
Services
Core offering1 text field

Achieve TMS provides in-person depression treatment services at physical clinic locations, delivering FDA-cleared NeuroStar TMS (Transcranial Magnetic Stimulation) therapy and FDA-approved SPRAVATO (esketamine) nasal spray treatments to adults suffering from depression, including treatment-resistant depression and major depressive disorder with suicidal thoughts. Treatments are administered by clinical staff and billed primarily through major insurance carriers, with Medicare and Medicaid coverage available at various locations and the company handling all insurance paperwork, claims, and appeals on the patient's behalf.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Greenbrook TMS (Achieve TMS) offers two distinct FDA-approved/cleared depression treatments: NeuroStar TMS Therapy (FDA-cleared transcranial magnetic stimulation) and SPRAVATO® (FDA-approved esketamine nasal spray). NeuroStar TMS is a non-medication, non-invasive treatment that targets specific brain areas, while SPRAVATO® is an FDA-approved esketamine formulation delivered as a nasal spray for treatment-resistant depression. Both treatments can be used as stand-alone therapy or in combination with existing medications.

Partnership4 partners
Strategic tierCoreTypeTechnology or Integration
Description

Greenbrook provides NeuroStar TMS Therapy, an FDA-cleared non-invasive depression treatment using transcranial magnetic stimulation technology developed by Neuronetics. The company operates as a provider of this technology at their clinic locations.

Strategic tierCoreTypeTechnology or Integration
Description

Greenbrook offers SPRAVATO (esketamine) nasal spray, an FDA-approved ketamine-based antidepressant treatment for treatment-resistant depression, licensed from Janssen Pharmaceuticals.

Strategic tierCoreTypeOthers
Description

The company works directly with insurance companies to get coverage, file and process claims, and help with appeals when needed. Services covered by major insurance companies including Medicare and Medicaid at various locations.

Strategic tierMinorTypeOthers
Description

LegitScript verification partner providing healthcare merchant monitoring and verification services for the company's website.

Recent move2 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Cerebral is a digital mental health platform that provides online psychiatry and medication management. It represents the emerging telehealth-and-medication front door that competes for newly diagnosed depression patients before they progress to TRD.

TypeEmerging player
Description

Talkspace is an online therapy and psychiatry platform. It competes for the same adult depression patient pool via a fully remote, lower-friction model, and is a relevant comparator on patient acquisition economics.

TypeDirect peer
Description

Mindpath Health is a multi-state outpatient psychiatry and psychology group that integrates TMS and SPRAVATO into its treatment offerings. It is a direct specialty competitor for depression referrals and treated patients.

TypeBroad incumbent
Description

LifeStance is one of the largest US outpatient mental health platforms, offering psychiatric evaluation, therapy, and increasingly TMS and esketamine services. It competes for the same patient population and referral channels at much greater scale.

TypeBroad incumbent
Description

Acadia operates behavioral health hospitals and outpatient programs across the US, including psychiatric residential and intensive outpatient services. It competes for higher-acuity behavioral health patients and the payer relationships that fund them.

TypeBroad incumbent
Description

Neuronetics manufactures NeuroStar TMS, the device that anchors Achieve TMS's core service. As the upstream technology owner and a publicly traded firm (NASDAQ: NTGN), it is both a critical supplier and a comparable public-market benchmark for TMS economics.

TypeBroad incumbent
Description

Brainsway develops and commercializes deep TMS systems for depression and other psychiatric indications. It is a direct competitor to Neuronetics in the TMS device market and shapes the competitive landscape for any clinic building a TMS offering.

TypeEmerging player
Description

Brightside Health combines online psychiatric care with pharmacology and is expanding into interventional depression treatments. It is an emerging competitor in the digital-to-interventional depression care pathway.

9Magstim
TypeBroad incumbent
Description

Magstim is a long-established manufacturer of TMS stimulators and supplies research and clinical-grade systems globally. Its presence in the device market influences technology choice and pricing for any TMS clinic operator.

TypeDirect peer
Description

Greenbrook operates a multi-state network of outpatient clinics delivering NeuroStar TMS and SPRAVATO under the same dual-modality model that defines Achieve TMS. It is the closest direct competitor by product mix, patient population, and clinical operating model.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Achieve TMS

Mental Health Servicesachievetms.com

Achieve TMS is a private healthcare provider founded in 2016 in San Diego that operates clinics delivering FDA-cleared NeuroStar TMS therapy and FDA-approved SPRAVATO esketamine treatments to adults with depression, particularly treatment-resistant depression.

What Achieve TMS does

Achieve TMS is a private healthcare services provider founded in 2016 and headquartered in San Diego that delivers FDA-cleared and FDA-approved depression treatments to adults suffering from major depressive disorder, including treatment-resistant depression. The company operates physical clinic locations where patients receive in-person treatment, and its core offerings are NeuroStar TMS Therapy (transcranial magnetic stimulation, FDA-cleared) and SPRAVATO (esketamine nasal spray, FDA-approved), both supplied through technology and licensing partnerships with Neuronetics and Janssen Pharmaceuticals respectively. The treatments target adults with depression, particularly those who have not achieved relief through traditional antidepressant medications or talk therapy, and patients with MDD accompanied by suicidal ideation.

The company generates revenue by delivering recurring treatment services at clinic locations, with most major insurance plans, Medicare, and Medicaid providing coverage at various sites. Pricing is not publicly disclosed; instead, the company manages the entire insurance workflow on behalf of patients — including coverage verification, claims filing, and appeals — which serves as a patient-friction-reduction mechanism and a core part of the value proposition. Patient acquisition runs through direct-to-consumer channels including a toll-free consultation line, online PHQ-9/PHQ-10 self-assessment quizzes, website content, and patient testimonial stories, with a separate provider-referral pathway for clinicians.

The business model is that of a clinic operator rather than a product manufacturer: Achieve TMS delivers externally-developed FDA-regulated treatments through its own physical footprint and operational infrastructure. Strategic relationships with the technology licensors (Neuronetics, Janssen), insurance carriers, and LegitScript (for healthcare merchant verification) form the operational backbone, and HIPAA compliance is maintained for patient data handling. No funding rounds, M&A activity, leadership details, or headcount data are disclosed in the source material, limiting visibility into the company's scale and capital structure.

Achieve TMS firmographics

Firmographics
Name
Achieve TMS
Legal name
Greenbrook TMS NeuroHealth Centers
Website
https://achievetms.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Achieve TMS is a private healthcare provider founded in 2016 in San Diego that operates clinics delivering FDA-cleared NeuroStar TMS therapy and FDA-approved SPRAVATO esketamine treatments to adults with depression, particularly treatment-resistant depression.
Ownership category
akta.pro rank

Where Achieve TMS is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Achieve TMS business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Patient Treatment Services: Revenue generated from providing TMS therapy and esketamine treatment services to patients at clinic locations. Treatments are typically covered by insurance including Medicare and Medicaid.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Achieve TMS product offering

Product offering

Core offering

Achieve TMS provides in-person depression treatment services at physical clinic locations, delivering FDA-cleared NeuroStar TMS (Transcranial Magnetic Stimulation) therapy and FDA-approved SPRAVATO (esketamine) nasal spray treatments to adults suffering from depression, including treatment-resistant depression and major depressive disorder with suicidal thoughts. Treatments are administered by clinical staff and billed primarily through major insurance carriers, with Medicare and Medicaid coverage available at various locations and the company handling all insurance paperwork, claims, and appeals on the patient's behalf.

Product overview

Greenbrook TMS (Achieve TMS) offers two distinct FDA-approved/cleared depression treatments: NeuroStar TMS Therapy (FDA-cleared transcranial magnetic stimulation) and SPRAVATO® (FDA-approved esketamine nasal spray). NeuroStar TMS is a non-medication, non-invasive treatment that targets specific brain areas, while SPRAVATO® is an FDA-approved esketamine formulation delivered as a nasal spray for treatment-resistant depression. Both treatments can be used as stand-alone therapy or in combination with existing medications.

Differentiator

Problem solved

Functional benefit

Companies that use Achieve TMS

Customer profile

Named customers3 records

Segments1 record

Ideal customer profiles1 record

Achieve TMS technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Achieve TMS partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and minor.

  • NeuroStar (Neuronetics)coreTechnology or IntegrationGreenbrook provides NeuroStar TMS Therapy, an FDA-cleared non-invasive depression treatment using transcranial magnetic stimulation technology developed by Neuronetics. The company operates as a provider of this technology at their clinic locations.
  • Janssen (SPRAVATO)coreTechnology or IntegrationGreenbrook offers SPRAVATO (esketamine) nasal spray, an FDA-approved ketamine-based antidepressant treatment for treatment-resistant depression, licensed from Janssen Pharmaceuticals.
  • Insurance CompaniescoreOthersThe company works directly with insurance companies to get coverage, file and process claims, and help with appeals when needed. Services covered by major insurance companies including Medicare and Medicaid at various locations.
  • LegitScriptminorOthersLegitScript verification partner providing healthcare merchant monitoring and verification services for the company's website.

Recent moves2 records

Expansion highlights4 records

Achieve TMS competitors and assessment

Company assessment

Emerging players

  • Cerebral: Cerebral is a digital mental health platform that provides online psychiatry and medication management. It represents the emerging telehealth-and-medication front door that competes for newly diagnosed depression patients before they progress to TRD.
  • Talkspace: Talkspace is an online therapy and psychiatry platform. It competes for the same adult depression patient pool via a fully remote, lower-friction model, and is a relevant comparator on patient acquisition economics.
  • Brightside Health: Brightside Health combines online psychiatric care with pharmacology and is expanding into interventional depression treatments. It is an emerging competitor in the digital-to-interventional depression care pathway.

Direct peers

  • Mindpath Health: Mindpath Health is a multi-state outpatient psychiatry and psychology group that integrates TMS and SPRAVATO into its treatment offerings. It is a direct specialty competitor for depression referrals and treated patients.
  • Greenbrook TMS NeuroHealth Centers: Greenbrook operates a multi-state network of outpatient clinics delivering NeuroStar TMS and SPRAVATO under the same dual-modality model that defines Achieve TMS. It is the closest direct competitor by product mix, patient population, and clinical operating model.

Broad incumbents

  • LifeStance Health: LifeStance is one of the largest US outpatient mental health platforms, offering psychiatric evaluation, therapy, and increasingly TMS and esketamine services. It competes for the same patient population and referral channels at much greater scale.
  • Acadia Healthcare: Acadia operates behavioral health hospitals and outpatient programs across the US, including psychiatric residential and intensive outpatient services. It competes for higher-acuity behavioral health patients and the payer relationships that fund them.
  • Neuronetics: Neuronetics manufactures NeuroStar TMS, the device that anchors Achieve TMS's core service. As the upstream technology owner and a publicly traded firm (NASDAQ: NTGN), it is both a critical supplier and a comparable public-market benchmark for TMS economics.
  • Brainsway: Brainsway develops and commercializes deep TMS systems for depression and other psychiatric indications. It is a direct competitor to Neuronetics in the TMS device market and shapes the competitive landscape for any clinic building a TMS offering.
  • Magstim: Magstim is a long-established manufacturer of TMS stimulators and supplies research and clinical-grade systems globally. Its presence in the device market influences technology choice and pricing for any TMS clinic operator.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Achieve TMS social profiles

Digital presence

Achieve TMS compliance and trust

Trust signal

Compliance2 records

Achieve TMS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Achieve TMS leadership team

Management profile

Number of profiles

Achieve TMS funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Achieve TMS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Achieve TMS

What does Achieve TMS do?

Achieve TMS provides in-person depression treatment services at physical clinic locations, delivering FDA-cleared NeuroStar TMS (Transcranial Magnetic Stimulation) therapy and FDA-approved SPRAVATO (esketamine) nasal spray treatments to adults suffering from depression, including treatment-resistant depression and major depressive disorder with suicidal thoughts. Treatments are administered by clinical staff and billed primarily through major insurance carriers, with Medicare and Medicaid coverage available at various locations and the company handling all insurance paperwork, claims, and appeals on the patient's behalf.

Is Achieve TMS a public or private company?

Achieve TMS is a private company. It is classified as unknown and is currently operating.

When was Achieve TMS founded?

Achieve TMS was founded in 2016. It employs 11 to 50 people.

Where is Achieve TMS based?

Achieve TMS is headquartered in San Diego, United States, in the North America region.

How does Achieve TMS make money?

One revenue line is on record: patient Treatment Services.

Who are Achieve TMS's main competitors?

Emerging players on record are Cerebral, Talkspace and Brightside Health. Direct peers are Mindpath Health and Greenbrook TMS NeuroHealth Centers. Broad incumbents are LifeStance Health, Acadia Healthcare, Neuronetics, Brainsway and Magstim.

Does Achieve TMS have an API?

No public API is recorded for Achieve TMS.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PrwebLee Ann Gee, MD, Joins TMS Center of AlaskaLee Ann Gee, MD, joins Achieve TMS Center of Alaska on February 18, 2020. She is a board-certified psychiatrist specializing in medication management and psychotherapy. The center offers FDA-cleared TMS therapy for OCD and depression, with a fourth center opening in South Anchorage in mid-March.GlobeNewswireAchieve TMS, the second largest TMS group in the US, starts using Nexstim SmartFocus® TMS technologyNexstim placed its NBT system with Achieve TMS in La Jolla, CA, the second-largest TMS group in the US with 24 clinics. The system uses SmartFocus technology for major depressive disorder treatment. Nexstim expects to add Achieve's patient data to its growing registry.GlobeNewswireAchieve TMS Announces Grand Opening of New Location in Newton, MassachusettsAchieve TMS opened a new facility in Newton, Massachusetts, its 11th in the state, with a grand opening on May 31. The company offers BrainsWay's Deep TMS for treatment-resistant depression, with 16 million Americans affected. The firm plans to expand to Connecticut and other New England states.PR NewswireAchieve TMS, Nation's Largest Deep TMS* Provider for Depression, Opens Two Achieve TMS LA CentersAchieve TMS, the nation's largest deep TMS provider for depression treatment, is opening two new centers in Simi Valley and Calabasas this month, with a third planned for Thousand Oaks in March. The new Achieve TMS LA centers represent a partnership between Dr. Mindy Werner-Crohn of Calabasas Behavioral Health and Achieve TMS, expanding access to FDA-approved deep transcranial magnetic stimulation therapy in the greater Los Angeles area. Free TMS assessments are now available at both operating locations.PR NewswireAchieve TMS - Nation's Largest and Most Experienced TMS Provider Opens in Beaverton, OregonAchieve TMS has opened a second state-of-the-art center in Beaverton, Oregon, to provide deep Transcranial Magnetic Stimulation (dTMS) treatments for major depressive disorder. The facility utilizes FDA-approved technology to treat patients who are unable or unwilling to take medication, with sessions scheduled five days per week for four to six weeks.PR NewswireLandmark TMS Provider - Achieve TMS - Opening in Claremont, CAAchieve TMS, a provider of deep Transcranial Magnetic Stimulation (dTMS) for depression treatment, announced it will open a new center in Claremont, California on September 1, 2017. The treatment is FDA-approved, covered by major health insurance, and supported by over 60 clinical studies demonstrating statistically significant response and remission rates for treatment-resistant depression. The center aims to expand access to this non-invasive therapy, which involves magnetic pulses targeting the brain's mood center with 20-minute sessions five days per week for 4-6 weeks.PrwebAchieve TMS Opens New Location in San Clemente, California to Offer Brainsway Deep Transcranial Magnetic Stimulation for the Treatment of DepressionAchieve TMS is opening a new office in San Clemente, California, to offer Brainsway deep transcranial magnetic stimulation (dTMS) for depression. The FDA-cleared treatment has been studied in over 60 clinical trials and requires no anesthesia. The company describes it as a non-invasive, 20-minute session that improves mood and sleep.